Update on HER-2 as a target for cancer therapy: Alternative strategies for targeting the epidermal growth factor system in cancer

AUTOR(ES)

Gullick, William J

FONTE

BioMed Central

RESUMO

The epidermal growth factor (EGF) family of ligands and receptors interact to influence cell division, differentiation and motility. Much evidence supports their importance in causing and sustaining cell transformation in model systems and in human cancer. The exact mechanism by which this is achieved varies in different tumour types and from case to case. The EGF system is a target for new types of targeted chemotherapy. The choice of strategy will depend on the mechanism involved, however, and several approaches are under development or evaluation in clinical trials. Each will have a different spectrum of side effects and the potential for development of drug resistance.

Documentos Relacionados

• Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
• Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment
• Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
• Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members
• HER-2 gene amplification can be acquired as breast cancer progresses